Market capitalization | $1.24b |
Enterprise Value | $1.25b |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | 220.65 |
EV/Sales (TTM) EV/Sales | 10.11 |
P/S ratio (TTM) P/S ratio | 10.07 |
P/B ratio (TTM) P/B ratio | 3.80 |
Revenue growth (TTM) Revenue growth | -20.31% |
Revenue (TTM) Revenue | $123.36m |
As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.
10 Analysts have issued a BioLife Solutions, Inc. forecast:
10 Analysts have issued a BioLife Solutions, Inc. forecast:
Sep '24 |
+/-
%
|
||
Revenue | 123 123 |
20%
20%
|
|
Gross Profit | 49 49 |
8%
8%
|
|
EBITDA | -18 -18 |
52%
52%
|
EBIT (Operating Income) EBIT | -28 -28 |
49%
49%
|
Net Profit | -37 -37 |
64%
64%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
BioLife Solutions, Inc. engages in the development, manufacture, and marketing of biopreservation tools for cells and tissues. Its product offerings include proprietary hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs; generic blood stem cell freezing and cell thawing media products; and custom product formulation and custom packaging services. The company was founded by Boris Rubinsky in 1998 and it is headquartered in Bothell, WA.
Head office | United States |
CEO | Roderick Greef |
Employees | 414 |
Founded | 1987 |
Website | www.biolifesolutions.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.